<DOC>
	<DOCNO>NCT00722319</DOCNO>
	<brief_summary>Patients warfarin treatment pose particular problem undergo percutaneous coronary intervention stent implantation ( PCI-S ) , poor definition optimal antithrombotic strategy adopt peri-procedurally 4 ( ) week PCI-S , dual antiplatelet therapy aspirin clopidogrel recommend . In absence solid evidence-based data , definite recommendation management patient subset currently give guideline percutaneous coronary intervention issue prominent Cardiology Associations . Indeed , high variability report current antithrombotic strategy , may consist either temporary substitution warfarin dual antiplatelet treatment combination warfarin aspirin clopidogrel . Peri-procedural bridging therapy either intravenous unfractionated subcutaneous low-molecular-weight heparin also variably carry . Purpose registry determine patient warfarin treatment undergoing PCI-S : 1 ) contemporary peri-procedural medium-term antithrombotic management ; 2 ) relative safety efficacy various antithrombotic regimen .</brief_summary>
	<brief_title>Ongoing WARfarin Coronary STENTing</brief_title>
	<detailed_description>Patients oral anticoagulation vitamin-K antagonist undergo PCI-S prospectively include registry follow 12 month</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients ongoing warfarin treatment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>oral anticoagulation</keyword>
	<keyword>warfarin</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>stent</keyword>
	<keyword>antiplatelet agent</keyword>
</DOC>